A
Advaccine Biotech
Developing prophylactic and therapeutic vaccines for global diseases
About Advaccine Biotech
Advaccine Biotech is a clinical-stage biopharmaceutical company founded in 2009 by Dr. Bin Wang, an Emeritus Professor from Fudan University. The company focuses on developing, manufacturing, and commercializing prophylactic and therapeutic vaccines to address infectious diseases, cancer, and autoimmune diseases.
The company's pipeline includes candidates for diseases with significant unmet medical needs, such as Respiratory Syncytial Virus (RSV), Hepatitis B (HBV), and various cancers. One of its most advanced candidates is ADV110, a protein subunit RSV vaccine designed for children and the elderly, which has entered Phase 2 clinical trials. Advaccine utilizes proprietary technology platforms, including novel adjuvants and a cellular immunity assessment platform, to accelerate the development of its vaccine candidates. A key area of focus has been DNA vaccine technology, which offers advantages in stability, storage, and rapid production compared to traditional vaccines.
Advaccine gained prominence through its strategic collaboration with U.S.-based Inovio Pharmaceuticals to co-develop and commercialize a DNA vaccine for COVID-19, INO-4800, in Greater China. This partnership leveraged Advaccine's regional expertise and its large-scale GMP plasmid manufacturing facility in Suzhou, capable of producing over 100 million vaccine doses annually. The business model involves in-house research and development, strategic partnerships for co-development and commercialization, and in-licensing opportunities. Revenue generation is anticipated from product sales upon regulatory approval, milestone payments, and royalties from licensing agreements.
Source: Dealroom company dataAt a glance
- Headquarters
- Dongcheng District, China
- Sector
- Biotech & Life Sciences
News
Open roles
Advaccine Biotech in the Dongcheng District ecosystem
The Advaccine Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- FCFortune Capital
Star Capital
Series B and later2 investors entered at this stage
Matrix Partners China- HCHony Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Advaccine Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Advaccine Biotech on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


